Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | SQOR | Q9Y6N5 | 3/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | TOP1 | P11387 | 2/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015684 | 0.92 | TGFBR1 (0.46) | TGFBR1MAPK14SQORPDK2GRM5 | |
| SCHEMBL18015493 | 0.91 | TGFBR1 (0.45) | TGFBR1PDK2GRM5LDHAMEN1 | |
| SCHEMBL18015498 | 0.88 | LDHA (0.40) | TGFBR1MAPK14PDK2GRM5LDHA | |
| SCHEMBL21020819 | 0.87 | LDHA (0.43) | TGFBR1PDK2GRM5LDHA | |
| SCHEMBL18015380 | 0.87 | PDK2 (0.45) | TGFBR1PDK2GRM5LMNA | |
| SCHEMBL18015496 | 0.85 | LDHA (0.48) | TGFBR1GRM5LDHA | |
| SCHEMBL18015497 | 0.85 | GRM5 (0.42) | TGFBR1MAPK14GRM5LDHA | |
| SCHEMBL19933730 | 0.84 | LDHA (0.42) | TGFBR1MAPK14TOP1LDHAALOX5AP | |
| SCHEMBL19794359 | 0.83 | LDHA (0.48) | SQORTOP1LDHAALOX5APFEN1 | |
| SCHEMBL20068726 | 0.82 | LDHA (0.43) | TGFBR1TOP1LDHAALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | TGFBR1 2080/4885MAPK14 4612/4885SQOR 637/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | TGFBR1 4348/4885MAPK14 4458/4885SQOR 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.